Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735, a dual glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonist, in healthy adults and otherwise healthy adults who have an increased body mass index

Next Previous
Trial Profile

A Phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735, a dual glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonist, in healthy adults and otherwise healthy adults who have an increased body mass index

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VK 2735 (Primary)
  • Indications Diabetes mellitus; Non-alcoholic steatohepatitis; Obesity
  • Focus Adverse reactions; First in man
  • Sponsors Viking Therapeutics

Most Recent Events

  • 04 Nov 2024 According to an Viking Therapeutics media release, data from this study presented at the Obesity Week 2024
  • 04 Nov 2024 Results published in the Viking Therapeutics Media Release
  • 28 Oct 2024 According to an Viking Therapeutics media release, data from this study will be presented at the ObesityWeek 2024 on Nov 3.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top